These results underscore the importance of the miR-26a-1-3p/MDM2/p53/SLC7A11 pathway in facilitating sanggenol L-induced ferroptosis, positioning it as a promising therapeutic option for NSCLC (Table 2) (Figure 2) (Fu et al., 2024). This evidence concerns the gene TP53 and non-small cell lung carcinoma.